Ardelyx/$ARDX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Ardelyx

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ticker

$ARDX
Primary listing

Industry

Biotechnology

Employees

395

ISIN

US0396971071

Ardelyx Metrics

BasicAdvanced
$1B
-
-$0.23
0.76
-

What the Analysts think about Ardelyx

Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.

Bulls say / Bears say

Ardelyx's tenapanor received approval in China for treating hyperphosphatemia, triggering a $5 million milestone payment and potential future royalties, indicating strong international market expansion. (stocktitan.net)
The company reported a significant revenue increase of 237.9% to $116.13 million in Q4 2024, surpassing analyst expectations and demonstrating robust financial growth. (tradingview.com)
Analysts maintain a 'buy' rating on Ardelyx, with a consensus 12-month price target of $10.50, reflecting confidence in the company's future performance. (tradingview.com)
In Q1 2025, Ardelyx reported a net loss of $41.14 million, with an adjusted loss per share of 17 cents, missing analyst expectations and indicating financial challenges. (tradingview.com)
Research and development expenses increased to $14.9 million in Q1 2025 from $10.6 million in the same period of 2024, potentially impacting profitability. (finviz.com)
HC Wainwright downgraded Ardelyx from a 'buy' to a 'neutral' rating, lowering the price target from $11.00 to $5.50, reflecting reduced confidence in the stock's outlook. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

Ardelyx Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ardelyx Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs